Max Chat
Calendrier des promotions Centogene N.V.
Calendrier avancé
Graphique simple
À propos de l'entreprise Centogene N.V.
Centogene N.V., together with its subsidiaries, engages in the research and development of products for human genetics in Europe, the Middle East, North America, Latin America, and the Asia Pacific. It provides data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. It operates through two segments: Pharmaceutical and Diagnostics. The company provides target and drug screening, clinical development, market access and expansion, as well as CENTOGENE Biodatabank licenses and insight report services. In addition, it offers various services, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.Paramètres de base
IPO date
2019-11-07
ISIN
NL0014040206
Industry
Health Care Providers & Services
Sector
Health Care
Валюта
usd
Валюта отчета
eur
Сайт
Grade
Sous-estimation
| Nom | Signification | Grade |
| P/S | 0.6114 | 10 |
| P/BV | -1.48 | 0 |
| P/E | 0 | 0 |
Efficacité
| Nom | Signification | Grade |
| ROA | -45.07 | 0 |
| ROE | 137.55 | 10 |
| ROIC | 0 | 0 |
Dividendes
| Nom | Signification | Grade |
| Rendement en dividendes | 0 | 0 |
| DSI | 0 | 0 |
| Croissance moyenne du dividende | 0 | 0 |
Devoir
| Nom | Signification | Grade |
| Debt/EBITDA | -2.2 | 10 |
| Debt/Ratio | 0.8801 | 9 |
| Debt/Equity | -4.94 | 10 |
Impulsion de croissance
| Nom | Signification | Grade |
| Rentabilité Revenue, % | -2.54 | 0 |
| Rentabilité Ebitda, % | 142.23 | 10 |
| Rentabilité EPS, % | -94.96 | 0 |
paper.price.prices
| Prix | Common.min. | Common.max. | Changement | paper.changes_in_industry | paper.changes_in_index | |
| common.calendar.number_days.1 | 0.147 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
| common.calendar.number_days.7d | 0.147 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
| common.calendar.number_days.30d | 0.162 $ | 0.147 $ | 0.147 $ | -9.26 % | 0 % | 0 % |
| common.calendar.number_days.90d | 0.2 $ | 0.14 $ | 0.2 $ | -26.5 % | 0 % | 0 % |
| common.calendar.number_days.180d | 0.13 $ | 0.1211 $ | 0.2 $ | 13.08 % | 0 % | 0 % |
| common.calendar.number_days.1y | 0.14 $ | 0.065 $ | 0.54 $ | 5 % | 0 % | 0 % |
| common.calendar.number_days.3y | 1.43 $ | 0.065 $ | 2.2 $ | -89.72 % | 0 % | 0 % |
| common.calendar.number_days.5y | 12.99 $ | 0.065 $ | 13.94 $ | -98.87 % | 0 % | 0 % |
| common.calendar.number_days.10y | 0.065 $ | 0.065 $ | 25.16 $ | 226.15 % | 0 % | 0 % |
| common.calendar.number_days.ytd | 0.14 $ | 0.1211 $ | 0.2 $ | 5 % | 0 % | 0 % |
Principaux propriétaires
Entreprises similaires
P/E & P/BV
Gestion d'entreprise
| Superviseur | Titre d'emploi | Paiement | Année de naissance |
| Ms. Kim Stratton | CEO & Member of Management Board | 932.62k | 1962 (63 année) |
| Mr. Jose Miguel Coego Rios | CFO, Legal & IT and Member of Management Board | 323.87k | 1974 (51 année) |
| Dr. Peter Bauer M.D. | Interim MD, Chief Medical & Genomic Officer and Member of Management Board | 186.31k | 1970 (55 années) |
| Dr. Andrin Oswald M.D., Ph.D. | Advisor | 943.45k | 1972 (53 année) |
| Mr. Ian Rentsch | Chief Commercial Officer & GM of Pharma | N/A | 1976 (49 années) |
Informations sur l'entreprise
Adresse: Germany, Rostock, Am Strande 7 - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.centogene.com
Site web: https://www.centogene.com
